Status:
COMPLETED
Antibodies in Repeated Influenza Vaccination (ARIVA) Study
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
University of Oslo
University of Oxford
Conditions:
Vaccine Response Impaired
Eligibility:
All Genders
18+ years
Brief Summary
Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maxima...
Eligibility Criteria
Inclusion
- influenza vaccination (QIIV) independent of the study
- age \>18 yo
Exclusion
- no vaccination
- current acute illness
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04059991
Start Date
November 1 2017
End Date
March 31 2021
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Switzerland